Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000487499 | SCV000109878 | uncertain significance | not provided | 2013-01-28 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000487499 | SCV000574959 | uncertain significance | not provided | 2019-05-01 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000487499 | SCV000694401 | uncertain significance | not provided | 2016-09-21 | criteria provided, single submitter | clinical testing | Variant summary: The ATP7B c.1621G>A (p.Glu541Lys) variant involves the alteration of a non-conserved nucleotide located in the HMA domain (heavy-metal-associated) domain of ATP7B. 4/4 in silico tools predict a benign outcome for this substitution (SNPs&GO not captured due to low reliability index). This variant was found in 16/122754 control chromosomes at a frequency of 0.0001303, which does not exceed the estimated maximal expected allele frequency of a pathogenic ATP7B variant (0.0054006). To our knowledge, the variant was not reported in affected individuals at the time of classification. One clinical diagnostic laboratory classified this variant as uncertain significance. Due to the absence of clinical information and the lack of functional studies, the variant is classified as a variant of uncertain significance (VUS) until additional information becomes available. |
Counsyl | RCV000670794 | SCV000795693 | uncertain significance | Wilson disease | 2017-11-15 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000670794 | SCV002027172 | uncertain significance | Wilson disease | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000670794 | SCV002786372 | uncertain significance | Wilson disease | 2024-03-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000670794 | SCV003278194 | uncertain significance | Wilson disease | 2022-10-31 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 541 of the ATP7B protein (p.Glu541Lys). This variant is present in population databases (rs187046823, gnomAD 0.02%). This missense change has been observed in individual(s) with Wilson disease (PMID: 23235335). ClinVar contains an entry for this variant (Variation ID: 92386). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ATP7B protein function. Experimental studies have shown that this missense change does not substantially affect ATP7B function (PMID: 17919502). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV000487499 | SCV004226452 | uncertain significance | not provided | 2023-03-20 | criteria provided, single submitter | clinical testing | PM2 |
All of Us Research Program, |
RCV000670794 | SCV004846333 | uncertain significance | Wilson disease | 2024-09-23 | criteria provided, single submitter | clinical testing | This missense variant replaces glutamic acid with lysine at codon 541 of the ATP7B protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with Wilson disease (PMID: 23518715). This variant has been identified in 27/280880 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Laboratory for Molecular Medicine, |
RCV004017388 | SCV004848322 | likely benign | not specified | 2020-06-11 | criteria provided, single submitter | clinical testing | This variant was reported in at least two individuals with Wilson disease, however a second variant was not reported (Coffey 2013, Collet 2018). Variant is present in 0.01% (21/12624) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). It is listed in ClinVar as Uncertain Significance by 4 clinical laboratories (Variation ID 92386). Three mammals harbor a Lysine (Lys) at this amino acid position. For this reason, the variant is classified as likely benign. ACMG/AMP Criteria applied: BP4_Strong. |
Natera, |
RCV000670794 | SCV001463850 | uncertain significance | Wilson disease | 2020-09-16 | no assertion criteria provided | clinical testing |